225 related articles for article (PubMed ID: 17094441)
21. [Detection of minimal residual disease in children with neuroblastoma].
De Moerloose B; Swerts K
Verh K Acad Geneeskd Belg; 2005; 67(1):33-44. PubMed ID: 15828305
[TBL] [Abstract][Full Text] [Related]
22. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis.
Shimojima Y; Matsuda M; Gono T; Ishii W; Fushimi T; Hoshii Y; Yamada T; Ikeda S
Amyloid; 2005 Mar; 12(1):33-40. PubMed ID: 16076609
[TBL] [Abstract][Full Text] [Related]
23. NB84: a new monoclonal antibody for the recognition of neuroblastoma in routinely processed material.
Thomas JO; Nijjar J; Turley H; Micklem K; Gatter KC
J Pathol; 1991 Jan; 163(1):69-75. PubMed ID: 2002424
[TBL] [Abstract][Full Text] [Related]
24. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
[TBL] [Abstract][Full Text] [Related]
25. Combined use of multiparametric flow cytometry and cytomorphology to enhance detection of neuroblastoma metastatic cells in bone marrow.
Manenq C; Lesesve JF; Dreumont N; Massin F; Salignac S; Mansuy L; Chastagner P; Latger-Cannard V; Broséus J
Int J Lab Hematol; 2020 Feb; 42(1):52-60. PubMed ID: 31821742
[TBL] [Abstract][Full Text] [Related]
26. [The identification of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications].
Faulkner LB; Tamburini A; Tintori V; Paoli A; Tondo A; Bernini G; Medicina D; Brisigotti M; Corrias MV; Scaruffi P; Rosanda C; Lo Piccolo MS; Viscardi E; Milanaccio C; Garaventa A; De Bernardi B
Pediatr Med Chir; 1998; 20(3):175-8. PubMed ID: 9744008
[TBL] [Abstract][Full Text] [Related]
27. Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases.
Schumacher-Kuckelkorn R; Hero B; Ernestus K; Berthold F
Pediatr Blood Cancer; 2005 Aug; 45(2):195-201. PubMed ID: 15800908
[TBL] [Abstract][Full Text] [Related]
28. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer: flow cytometric methods for detection of bone marrow micrometastases.
Hussain M; Kukuruga M; Biggar S; Sakr W; Cummings G; Ensley J
Cytometry; 1996 Mar; 26(1):40-6. PubMed ID: 8809479
[TBL] [Abstract][Full Text] [Related]
30. Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) - a new perspective.
Talaulikar D; Shadbolt B; Bell J; Khan K; Dahlstrom JE; McDonald A; Pidcock M; Broomfield A
Histopathology; 2008 Feb; 52(3):340-7. PubMed ID: 18269585
[TBL] [Abstract][Full Text] [Related]
31. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry.
Nagai J; Ishida Y; Koga N; Tanaka Y; Ohnuma K; Toyoda Y; Katoh A; Hayabuchi Y; Kigasawa H
J Pediatr Hematol Oncol; 2000; 22(1):20-6. PubMed ID: 10695817
[TBL] [Abstract][Full Text] [Related]
32. Interference of bone marrow CD56
Theodorakos I; Paterakis G; Papadakis V; Vicha A; Topakas G; Jencova P; Karchilaki E; Taparkou A; Tsagarakis NJ; Polychronopoulou S
Pediatr Blood Cancer; 2019 Aug; 66(8):e27799. PubMed ID: 31066205
[TBL] [Abstract][Full Text] [Related]
33. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
Al-Mawali A; Gillis D; Hissaria P; Lewis I
Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
[TBL] [Abstract][Full Text] [Related]
34. Multiparameter flow cytometry characterization of MHC class I negative mouse bone marrow cells.
Quarta M; Stroka D; Keogh A; Sidler D; Avital I; Gloor B; Muraca M; Candinas D; Inderbitzin D
Med Sci Monit; 2008 Dec; 14(12):BR286-93. PubMed ID: 19043363
[TBL] [Abstract][Full Text] [Related]
35. [Significance of application of immunocytochemical detection of GD2 antigen in bone marrow in neuroblastoma patients].
Bolek-Marzec K; Balwierz W; Wieczorek A; Szewczyk K
Przegl Lek; 2010; 67(6):409-12. PubMed ID: 21344771
[TBL] [Abstract][Full Text] [Related]
36. Detection of the GD2+/CD56+/CD45- immunophenotype by flow cytometry in cerebrospinal fluids from a patient with retinoblastoma.
Shen H; Tang Y; Xu X; Tang H
Pediatr Hematol Oncol; 2013 Feb; 30(1):30-2. PubMed ID: 23126274
[TBL] [Abstract][Full Text] [Related]
37. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
38. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma.
Harrington AM; Hari P; Kroft SH
Am J Clin Pathol; 2009 Jul; 132(1):60-6. PubMed ID: 19864234
[TBL] [Abstract][Full Text] [Related]
39. Immunophenotype of isolated tumour cells in the blood, bone marrow and lymph nodes of patients with gastric cancer.
Pituch-Noworolska A; Drabik G; Szatanek R; Białas M; Kołodziejczyk P; Szczepanik A; Stachura J; Zembala M
Pol J Pathol; 2007; 58(2):93-7. PubMed ID: 17715675
[TBL] [Abstract][Full Text] [Related]
40. [Detection of residual cells contaminating the bone marrow in neuroblastoma. Apropos of 80 bone marrow evaluations].
Frappaz D; Maritaz O; Favrot MC; Philip I; Bernard JL; Bailly C; Gentilhomme O; Gentet JC; Zucker JM; Bouffet E
Arch Fr Pediatr; 1987 Nov; 44(9):771-8. PubMed ID: 3446068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
